Torsdag 26 December | 14:14:48 Europe / Stockholm

Kalender

Tid*
2022-01-26 - Bokslutskommuniké 2021
2021-07-14 - Kvartalsrapport 2021-Q2
2021-06-30 - Årsstämma
2021-05-27 - X-dag ordinarie utdelning NATTO 0.00 NOK
2021-02-17 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-07-15 - Kvartalsrapport 2020-Q2
2020-06-22 - X-dag ordinarie utdelning NATTO 0.00 NOK
2020-06-19 - Årsstämma
2020-05-06 - Kvartalsrapport 2020-Q1
2020-02-19 - Bokslutskommuniké 2019
2019-11-13 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-31 - X-dag ordinarie utdelning NATTO 0.00 NOK
2019-05-29 - Årsstämma
2019-04-30 - Kvartalsrapport 2019-Q1
2019-02-13 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-31 - X-dag ordinarie utdelning NATTO 0.00 NOK
2018-05-30 - Årsstämma
2018-02-08 - Bokslutskommuniké 2017
2017-11-24 - Extra Bolagsstämma 2017
2017-08-16 - Kvartalsrapport 2017-Q2
2017-05-16 - X-dag ordinarie utdelning NATTO 0.00 NOK
2017-05-15 - Årsstämma
2017-05-15 - Kapitalmarknadsdag 2017
2017-05-15 - Kvartalsrapport 2017-Q1
2017-02-08 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-20 - Årsstämma
2016-05-20 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
2015-11-25 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
2014-11-26 - Kvartalsrapport 2014-Q3
2014-08-27 - Kvartalsrapport 2014-Q2
2014-05-27 - Kvartalsrapport 2014-Q1
2014-02-17 - Bokslutskommuniké 2013
2013-11-26 - Kvartalsrapport 2013-Q3
2013-08-27 - Kvartalsrapport 2013-Q2
2013-05-22 - Kvartalsrapport 2013-Q1
2013-02-28 - Bokslutskommuniké 2012
2012-11-15 - Kvartalsrapport 2012-Q3
2012-08-21 - Kvartalsrapport 2012-Q2
2012-05-16 - Kvartalsrapport 2012-Q1
2012-02-28 - Bokslutskommuniké 2011
2012-02-13 - Extra Bolagsstämma 2012
2011-11-17 - Kvartalsrapport 2011-Q3
2011-10-31 - Extra Bolagsstämma 2011
2011-08-18 - Kvartalsrapport 2011-Q2
2011-05-19 - Kvartalsrapport 2011-Q1
2011-02-25 - Bokslutskommuniké 2010

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriLäkemedel & Handel
NattoPharma är ett norskt bolag verksamma inom utveckling av läkemedel. Idag innehas störst fokus på utveckling av diverse kosttillskott. Ledande varumärken säljs huvudsakligen via MenaQ7, ett vitamintillskott av K2 karaktär. En stor del av verksamheten fokuserar på forskning och utveckling inom arbetsområdet, vilket sker via separata dotterbolag. Bolaget etablerades 2004 och har sitt huvudkontor i Oslo.
2020-02-19 08:15:10
Oslo, Norway (19 February 2020) - Based on the power of attorney granted at the
annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on May
29th, 2019, and the option program related to defined operational objectives
approved by the Board of Directors in 2019, the Board of Directors of
NattoPharma has in board proceedings February 18th, 2020 granted a total of 155
000 options to executive management, other employees and strategic partners.
Options are granted based on performance against defined criteria and metrics.

The following persons on the executive management team have been granted
options;

Name         Shares  Granted  Options Prior to Grant  Options after Grant
              Owned  Options
Kjetil          300   50 000                 225 100              275 100
Ramsøy, CEO     000
& CFO

Other employees and partners have been granted a total of 105 000 options.

The options have an exercise price equal the closing price on Oslo Axess on
February 18[th], 2020, which is equal to NOK 9,20. The options granted are
vested immediately and may be exercised up to and including March 31[st], 2023.

Further, in conjunction with the hiring of the new Chief Financial Officer in
NattoPharma the Board of Directors has in board proceedings February 18th, 2020
granted a total of 30,000 options to Robert Schrama who will start in the new
position on March 9th, 2020. Mr. Schrama holds no shares or options in
NattoPharma ASA prior to this grant. His total holding of shares and options
following this grant is 30,000 options.

The options will have an exercise price equal the closing price on Oslo Axess on
March 9th, 2020. The options granted are fully vested on September 9th, 2020 and
may be exercised up to and including March 31st, 2023.

X X X

For more information, please contact:

Kjetil Ramsøy,

CEO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.